Langerhans Cell-targeted mRNA Delivery: A Strategy for Dose-Sparing and Enhanced Anti-Tumor Immunity
Despite the success of mRNA therapeutics, challenges remain in optimizing immune responses and minimizing side effects. Cell-specific antigen delivery may help reduce required doses and improve vaccine efficacy. In this study, we report on the first targeted delivery system for mRNA to a specific subset of skin-resident antigen-presenting cells – Langerhans cells. By functionalizing lipid nanoparticles (LNPs) with a langerin-specific glycomimetic ligand, we achieve selective mRNA delivery to both murine and human primary Langerhans cells with minimal off-target uptake, at the same time resulting in significantly increased mRNA translation. This targeted mRNA delivery not only enhances antigen presentation and T cell responses but also enables dose-sparing and superior anti-tumor immunity compared to conventional immunization in a B16-OVA tumor model. Importantly, our platform’s high compatibility with various lipid nanoparticle formulations offers a flexible and precise tool for skin-directed mRNA delivery.
More information
—
Leadership Transition
Timm-H. Jessen Appointed Managing Director Cutanos GmbH announces a leadership transition as co-founder and CEO Dr. Robert Wawrzinek takes a break steps down from his role for personal reasons. Dr. Wawrzinek will continue to support the company as a board member and...
Research Paper Release
Langerhans Cell-targeted Protein Delivery Enhances Antigen-Specific Cellular Immune Response Targeted antigen delivery to immune cells, particularly dendritic cells, has emerged as a promising strategy to enhance therapeutic efficacy of vaccines, while minimizing...
BARDA VITAL Symposium in Berlin
Cutanos Wins BARDA VITAL Prize Challenge for Innovative Vaccine Technology! Vienna, Austria (July 1, 2024) – Cutanos GmbH, a biotechnology company based in Vienna, Austria, was awarded first place in the BARDA VITAL Prize (BVP) Challenge, endowed with USD 20,000 by...
New Team Member
Welcome Ramona Rîca and Litty Johnson, the latest additions to Cutanos' science Team! With pleasure we welcome Ramona and Litty and are excited to add even more expertise in immunology and material science to our projects! —
New Team Member
We welcome our new Scientist and Project Lead Klara Klein We are proud to welcome Klara to our team. With her vast expertise in immunology she is going to lead her own research project and will give valuable impacts in all of Cutanos' scientific endeavours! —
New Team Member
We welcome our new CFO/CBO Ulrich Platte The whole team is thrilled to announce Ulrich as our new CFO & CBO. We are beyond confident he will be a major asset to Cutanos and our next business development steps. Welcome, Ulrich! —
Cutanos and Pfizer team up
Cutanos and Pfizer team up to apply LC-TDS technology to autoimmune diseases Thanks to Pfizer's Emerging Science Fund, Cutanos will explore its immune cell-specific drug delivery system as a potential therapy platform for autoimmune disorders. In the next two...
New Team Members!
We Welcome our Newest Team Members! We are very happy to announce our latest additions to the team: Alexandra Sykora (Office Manager), Mirza Sarcevic and Gabriele Carta (Technical Assistants)! Welcome aboard! —
Green Labs Austria
Cutanos joins Green Labs Austria Initiative As a biotechnology lab Cutanos feels responsible to not only contribute to science but also carrying out experiments in a more sustainable fashion. Hence, we want to participate in Green Labs Austria vision to reduce...
ABA Podcast
ABA Podcast "𝗪𝗶𝗿𝘁𝘀𝗰𝗵𝗮𝗳𝘁 𝗶𝗺 ¾ 𝗧𝗮𝗸𝘁" — Doris Dobida talks with Cutanos' Co-Founder Robert Wawrzinek about starting a biotech company in Austria.